Research output per year
Research output per year
Personal profile
Headline
ASSOCIATE PROFESSOR Medicine, Hematology and Medical Oncology
Biography
Fingerprint
Dive into the research topics where Max Sung is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study
Piscaglia, F., Ikeda, K., Cheng, A. L., Kudo, M., Ikeda, M., Breder, V., Ryoo, B. Y., Mody, K., Ren, M., Ramji, Z. & Sung, M. W., 15 Apr 2024, In: Cancer. 130, 8, p. 1281-1291 11 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma
Garcia-Reyes, K., Gottlieb, R. A., Menon, K. M., Bishay, V., Patel, R., Patel, R., Nowakowski, S., Sung, M. W., Marron, T. U., Gansa, W. H., Zhang, J., Raja, S. C., Shilo, D., Fischman, A., Lookstein, R. & Kim, E., May 2024, In: Journal of Vascular and Interventional Radiology. 35, 5, p. 722-730.e1Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
Dasari, A., Hamilton, E. P., Falchook, G. S., Wang, J. S., Li, D., Sung, M. W., Chien, C., Nanda, S., Tucci, C., Hahka-Kemppinen, M. & Paulson, A. S., Jun 2023, In: Investigational New Drugs. 41, 3, p. 421-430 10 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Kudo, M., Finn, R. S., Ikeda, M., Sung, M. W., Baron, A. D., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., Pracht, M., Meyer, T., Nagao, S., Saito, K., Mody, K., Ramji, Z., Dubrovsky, L. & Llovet, J. M., 13 Nov 2023, In: Liver Cancer. 13, 4, p. 451-458 8 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
LEAP-002 Investigators, Dec 2023, In: The Lancet Oncology. 24, 12, p. 1399-1410 12 p.Research output: Contribution to journal › Article › peer-review
Open Access126 Scopus citations
Press/Media
-
Research Data from Mount Sinai Hospital Update Understanding of Liver Cancer (Radioembolization Plus Immune Checkpoint Inhibitor Therapy Compared With Radioembolization Plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular ...)
Kim, E., Patel, R., Fischman, , A., Bishay, V. & Sung, M.
26/06/24
1 item of Media coverage
Press/Media